<DOC>
	<DOCNO>NCT00879008</DOCNO>
	<brief_summary>In study data patient moderate severe acute exacerbation chronic bronchitis ( AECB ) collect . There two different cohort compare ( Moxifloxacin antibiotic ) concern effectiveness tolerance . It prospective study accomplish 100 ambulatory practice office .</brief_summary>
	<brief_title>SYMPROVE III : Health Services Research Study Treatment Moderate Severe Acute Exacerbations Chronic Bronchitis ( AECB )</brief_title>
	<detailed_description>The study design slightly change adapt target population . Due change study restart 8th December 2009 .</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Acute exacerbation chronic bronchitis Anthonisen type I II FEV1 &lt; 50 % Patient must ensure statutory health insurance Further contraindication prescribe pharmaceutical product must consider Patients change one cohort</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Disease Exacerbation</keyword>
	<keyword>Acute Exacerbations Chronic Bronchitis</keyword>
	<keyword>AECB</keyword>
	<keyword>Avelox</keyword>
	<keyword>Bronchitis</keyword>
</DOC>